Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma

Despite recent therapeutic advances that have doubled the median survival time of patients with multiple myeloma (MM), intratumor genetic heterogeneity contributes to disease progression and emergence of drug resistance. MicroRNAs (miRs), are noncoding small RNAs that play important roles in the reg...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Zhao, Jian-Jun, Chu, Zhang-Bo, Hu, Yu, Lin, Jianhong, Wang, Zhongqiu, Jiang, Meng, Chen, Ming, Wang, Xujun, Kang, Yue, Zhou, Yangsheng, Ni Chonghaile, Triona, Johncilla, Melanie E., Tai, Yu-Tzu, Cheng, Jin Q., Letai, Antony, Munshi, Nikhil C., Anderson, Kenneth C., Carrasco, Ruben D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4609291/
https://ncbi.nlm.nih.gov/pubmed/26249174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0457
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares